Endovascular Superselective Embolization of the Prostatic Arteries in the Treatment of Benign Prostatic Hyperplasia

نویسندگان

چکیده

Objective: The purpose of this study is to explore further a new minimally invasive method in order expand the surgical options for treating patients with benign prostatic hyperplasia as well evaluate efficacy and safety endovascular superselective embolization arteries hyperplasia. Material methods: group included 43 hyperplasia, aged 56 90 years. carried out period from February December 2019. All were determined by level prostate-specific antigen, ultrasound scan prostate bladder, uroflowmetry, used IPSS questionnaire. physical condition was assessed using American Society Anesthesiologists classification. Results: technical success operation form bilateral achieved 29 (67.5%) patients. Unolateral arteries, due complex anatomical structure or atherosclerotic changes, performed 14 (32.5%) observation 3 6 months. According maximum urination rate average value 8.5 ± 2.75 ml/s. Six months after volumetric urine flow during on 24.5 4.20 ml/s. Conclusion: Our results allow us an effective safe lower urinary tract symptoms men can be introduced promising treating.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

The histology of prostate tissue following prostatic artery embolization for the treatment of benign prostatic hyperplasia.

OBJECTIVE Prostatic artery embolization (PAE) for the treatment of patients with symptomatic benign prostatic hyperplasia (BPH) is believed to be a safe procedure with a low risk of adverse side effects. Artery embolization is a viable treatment option in patients who are refractory to the classic noninvasive treatments. Knowledge of the histological characteristics of prostate tissue following...

متن کامل

Prostatic artery embolization in the treatment of benign prostatic hyperplasia: short and medium follow-up.

To evaluate the short and mid-term results of prostatic artery embolization in patients with benign prostatic embolization. Retrospective study between March 2009 and June 2011 with 103 patients (mean age 66.8 years, 50-85) that met our inclusion criteria with symptomatic benign prostatic hyperplasia. The clinical outcome was evaluated by the International Prostate Symptom Score (IPSS), quality...

متن کامل

Prostatic arterial embolization to treat benign prostatic hyperplasia.

PURPOSE To evaluate whether prostatic arterial embolization (PAE) might be a feasible procedure to treat lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). MATERIALS AND METHODS Fifteen patients (age range, 62-82 years; mean age, 74.1 y) with symptomatic BPH after failure of medical treatment were selected for PAE with nonspherical 200-μm polyvinyl alcohol partic...

متن کامل

[Treatment of benign prostatic hyperplasia].

The first € price and the £ and $ price are net prices, subject to local VAT. Prices indicated with * include VAT for books; the €(D) includes 7% for Germany, the €(A) includes 10% for Austria. Prices indicated with ** include VAT for electronic products; 19% for Germany, 20% for Austria. All prices exclusive of carriage charges. Prices and other details are subject to change without notice. Al...

متن کامل

Prostate artery embolization for benign prostatic hyperplasia

Prostate artery embolization (PAE) has emerged as a promising treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH). We aim to provide an up-to-date review of this minimally invasive technique, including discussion of potential benefits and technical challenges. Current evidence suggests it is a promising and effective option for patients with large prostate...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Electronic journal of general medicine

سال: 2021

ISSN: ['2516-3507']

DOI: https://doi.org/10.29333/ejgm/10832